A 2 minute assessment to get a personalized mental health or alcohol recovery plan.
Nobody should start a medication without knowing what the exit looks like. Here is what the research actually says about stopping a GLP-1 used for drinking, and exactly where it goes quiet.
What You'll Discover:
• Why the alcohol research on GLP-1 medications is too short to answer the forever question.
• What happened to weight when trial participants came off semaglutide and tirzepatide.
• Why weight regain data is a reasonable proxy but not a real answer about cravings.
• How the naltrexone model is built differently, and why that matters for stopping.
• What open-ended off-label use actually costs.
• How to set up real reassessment points instead of guessing.
The question usually shows up before the first dose. People want to know whether this is a medication for a season or a medication for the rest of their life.
That is a smart thing to ask early, and it deserves a straight answer rather than a reassuring one.
The honest answer comes in three parts. What the research shows. What the research has not looked at yet. And how the two main medication options differ in ways that matter specifically to anyone thinking about an eventual exit.
The Alcohol Research Is Short, and That Is the Whole Problem
GLP-1 receptor agonists are approved for type 2 diabetes and for weight management. That list includes semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and liraglutide.
None of them is FDA-approved for alcohol use disorder. Using one to help with drinking is off-label, and the evidence behind it is genuinely emerging rather than settled.
The strongest randomized data so far comes from a nine-week trial of low-dose semaglutide in adults with alcohol use disorder. Compared with placebo, it reduced how much people drank in a lab self-administration session and reduced weekly craving.
Nine weeks is the entire window. The trial was not designed to follow anyone after they stopped, and it did not.
So when someone asks what happens to drinking six months after coming off a GLP-1, the truthful answer is that no published randomized trial has measured it. That is not us being cautious. That is the state of the field as of today.
What Actually Happens to Weight When People Stop
The adjacent question has been studied carefully, and the results line up across drugs.
In the STEP 1 trial extension, people who came off semaglutide 2.4 mg along with the structured lifestyle support regained about two-thirds of the weight they had lost over the following year.
Cardiometabolic markers drifted back in step with the weight. Blood pressure, lipids, and glycemic measures moved in the same direction.
The picture is not total reversal, though. At week 120, average weight was still 5.6 percent below where people started, and 48.2 percent of participants were still holding a clinically meaningful five percent loss.
Tirzepatide tells the same story. In the SURMOUNT-4 randomized withdrawal trial, people who switched to placebo after a 36-week lead-in gained back a mean of 14 percent over the next year. People who stayed on the medication lost another 5.5 percent.
The pattern across both drugs is present-tense. The effect is strongest while the medication is on board and it fades once the medication stops.
Why the Weight Data Is a Proxy, Not an Answer
It is reasonable to expect craving to behave somewhat like appetite here. The leading explanation for why these drugs touch drinking at all involves the same reward and satiety circuitry that governs food.
It is also reasonable to expect a difference. Drinking is a learned behavior wrapped in social context, routine, and stress response. Weight is not structured the same way.
What nobody can currently tell you is how much of the craving benefit survives discontinuation, or for how long. Anyone stating that confidently in either direction is extrapolating past the data.
There is one mechanical piece worth holding onto. A GLP-1 slows gastric emptying, which slows how fast alcohol reaches the small intestine where most of it gets absorbed.
That tends to lower and flatten the peak rather than sharpen it, which is the opposite of a claim that circulates constantly in consumer coverage.
That effect also disappears the moment the drug clears, along with everything else that depends on active drug levels.
How the Naltrexone Model Is Built Differently
Naltrexone is worth understanding here not as a competing product, but as a structurally different answer to the same question.
It has been FDA-approved for alcohol use disorder since 1994, and the oral form is a 50mg tablet. Three decades of approval is a different evidentiary position than off-label use.
Naltrexone blocks mu-opioid receptors. When you drink with it on board, the endorphin surge that normally drives dopamine release in the nucleus accumbens gets blunted, so the drink lands flatter than your brain expected.
The Extinction Idea in Plain Language
This is where the real conceptual difference lives.
If drinking repeatedly fails to deliver the payoff your brain has learned to expect, the learned association itself can weaken over time. That process is called extinction.
It is also the reason some prescribers have people take naltrexone specifically before drinking rather than simply every morning regardless of plans.
A recent review of opioid antagonist treatment, extinction, and reward memory walks through the model and the timing questions it raises.
The proposal is not that the drug suppresses craving while it is present. It is that repeated pairing rewrites what the brain expects from a drink.
The structural point matters more than the neuroscience. Learning, unlike a blood level, does not automatically clear when the prescription ends.
What the Naltrexone Evidence Shows After Treatment Ends
Care is needed here, because this is exactly where marketing tends to outrun data.
The extinction model is well described in animal research and supported by human laboratory work. Long-term controlled trials that follow people for years after naltrexone stops are limited, and individual outcomes vary a lot.
So the accurate framing is comparative rather than absolute. Naltrexone has a plausible mechanism by which benefit could persist after stopping. GLP-1 medications, as currently understood, do not have an equivalent described mechanism.
That is a real difference for anyone thinking about an exit. We go deeper on the head-to-head in our comparison of naltrexone and GLP-1 medications for alcohol use disorder.
What Stopping Looks Like, Side by Side
The Cost Question Nobody Puts in the Brochure
This is the part that gets skipped, and it changes real decisions.
If a medication only works while you are taking it, the price is not a month. It is a month multiplied by however many years you intend to hold onto the benefit.
Insurance compounds it. Because GLP-1s are not approved for alcohol use disorder, a prescription written for drinking is off-label, and off-label indications get denied routinely.
Coverage for a weight or diabetes indication is an entirely separate conversation with separate criteria, and qualifying for one does not mean qualifying for the other.
Oral naltrexone sits in a different bracket as an inexpensive generic. Our breakdown of what GLP-1 medications and naltrexone actually cost runs through the real numbers.
None of this makes a GLP-1 the wrong choice. It means the commitment should be priced accurately at the start rather than discovered in month eight.
So How Long Should You Plan to Stay On
The most defensible planning assumption right now is simple. Treat a GLP-1 used for drinking as an ongoing medication rather than a short course, and build in formal reassessment rather than a vague intention to see how it goes.
For most people that means a scheduled review at three months and again at six.
What gets reviewed should be specific and written down somewhere. Drinks per week. Heavy drinking days per month. Craving intensity on a simple one to ten scale. Side effect burden. Whether the original goal still holds.
If the medication is clearly working and tolerable, continuing is a reasonable call. If it is barely moving anything, that is useful information rather than a personal failure, and it is a reason to change the plan rather than white-knuckle it.
Reassessment is also the moment to notice that goals shift. Someone who started out wanting to cut weekend drinking often sits in a different place at month six than they expected in week one.
Building an Exit Ramp Instead of Guessing
Stopping a GLP-1 does not require a medical taper the way some medications do. Doses often get stepped down for comfort, not for safety.
The part that actually deserves planning is what replaces the support the medication was providing.
A useful exit conversation with a prescriber covers a handful of concrete things. What has genuinely changed in your drinking, and which triggers are still live.
It should also cover whether appetite and craving are likely to return together, and what the plan looks like if drinking starts climbing back.
It is also the natural point to ask whether adding naltrexone or switching to it makes sense, given that the two medications work through different mechanisms entirely.
We cover the discontinuation side of that in detail in our guide to what happens if you stop taking naltrexone.
Where a Combination Approach Fits
Some people are candidates for a physician-guided approach that uses a GLP-1 and naltrexone together, which Choose Your Horizon offers when it is clinically appropriate.
The logic behind it is that the two act on different parts of the problem. Naltrexone works on the reward a drink delivers. A GLP-1 works on appetitive drive, and for many people on weight at the same time.
It is not right for everyone, and that decision belongs with a prescriber who knows your medical history, your current medications, and what you are actually trying to accomplish.
If you want the background on how this medication class ended up in the alcohol conversation at all, our overview of GLP-1 medication for alcohol use covers it.
What Any of This Changes for You
A commitment question deserves a commitment answer, so here is ours in plain terms.
Plan for ongoing use. Set real reassessment dates at three and six months. Price the full commitment before you start rather than after. And make the call with a clinician rather than alone with a search engine at midnight.
The Honest Bottom Line
Whether you have to stay on a GLP-1 forever does not have a settled answer yet, and anyone handing you a confident one is filling a gap in the literature with opinion.
What is known is that the weight benefit largely reverses after stopping, in both semaglutide and tirzepatide trials.
What is likely but unproven is that the craving benefit behaves similarly, because both appear to run through drug that is actively present in your system.
What is different about naltrexone is that its proposed mechanism involves changing a learned expectation, and learning does not clear from the bloodstream on a schedule.
None of that makes one option the obvious winner. It makes them different tools with different exit profiles, and the right choice depends on your goals, your budget, your medical history, and how long you want to be taking something.
Wanting an exit plan is not a lack of commitment. It is what thinking clearly about a medication looks like, and it is a completely normal thing to raise with a prescriber on day one.
Frequently Asked Questions
Do alcohol cravings come back if you stop a GLP-1?
No published randomized trial has measured this yet. Based on how these medications work and on what happens to appetite and weight after stopping, some return of craving is a reasonable expectation.
Is naltrexone something you take forever too?
Not necessarily. Many people take it daily for a period and then reassess with a prescriber, and the extinction model suggests part of the benefit may come from changed learning rather than continuous blockade.
Can you take a GLP-1 and naltrexone at the same time?
Some people can, under physician supervision. The two work through different mechanisms, and whether a combination fits depends on your medical history, other medications, and goals.
Will insurance cover a GLP-1 prescribed for drinking?
Usually not. GLP-1 medications are not FDA-approved for alcohol use disorder, so a prescription written for that reason is off-label and commonly denied.
How long before I know whether a GLP-1 is helping my drinking?
Most clinicians reassess around three months, once the dose has been stepped up and a real pattern is visible. Tracking drinks per week and craving intensity from day one makes that conversation far more useful.
Does stopping a GLP-1 require tapering?
Not for safety reasons the way some medications do. Doses are often stepped down for comfort, and the more important planning question is what supports your drinking goals once the medication is gone.
Getting clear on the commitment before you start is exactly the right instinct. Take the online Alcohol Use Assessment to find out what Choose Your Horizon physicians would recommend for your situation.
